Achieving success in the Developing Asian Pharmaceutical Sector 2007-2011

Summary

Please Note: Reports are sold based on the user licenses indicated. The reports will be accessible in Flash format via an online reading room on the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order,the client will receive an email with information on accessing their purchase.

Will the economic growth in new Asian markets allow you to offset global problems? With the Japan market slow and stagnant what other countries in the region offer you the greatest opportunities and how can you succeed in them. This report tells you.

Asian Developing Markets for Pharmaceuticals, 2006-2011 delivers to you unique prospects for the largest developing pharmaceutical market - Asia.

This report predicts that all the leading developing markets will exhibit strong growth from 2006-2011. Rapid economic growth and large, under-served populations will drive that expansion in pharmaceutical revenues. There will be significant growth in sales of both branded and generic drugs through increasing demand from both public and private healthcare sectors.

This unique report concentrates on the following themes:

• Forecasts of sales revenues and growth rates for leading developing markets in Asia, from 2006-2011
• Drivers and opportunities in the markets you should be working in
• Restraints and threats in those markets
• Discussion of key players and important therapeutic areas
• Discussion of relevant regulatory, societal and economic issues
• Comparison of the prospects for revenuegeneration in Asia, Latin America and
• Central/Eastern Europe, with overall forecasts for those regions
• Who you should be working with and why

Why you should buy this report:

• To receive a comprehensive analysis of the prospects for developing regional and national markets for pharmaceuticals in Asia from 2006-2011, as well as comparative data for other developing regions
• To discover predicted revenues, growth rates and other key metrics for Asian developing markets from 2006-2011
• To determine the forces that influence pharmaceutical sales in the Asian developing markets:

Competitive characteristics of the market, both at - national and regional level

• Regulatory, technological, societal and political issues
• Drivers and restraints
• Strengths, weaknesses, opportunities and threats

The dominant pharmaceutical markets of North America, Western Europe and Japan currently account for approximately 85% of revenues for prescription drugs. However, there is concern about the relatively low growth of those established markets in recent years. Consequently, international pharmaceutical companies are very interested in raising their profile in the developing markets of Asia.

You cannot afford to ignore this expanding market. A small investment today will be the catalyst of a great return for your company tomorrow.

Unique benefits to you when you order this report

• Full searchable report when you buy the company or corporate editions
• Immediate access through our exclusive Reading Room
• You can access your report whichever country you are in without using harddrive space
• Primary research throughout. You will not find this information anywhere else
• Report stored in your reading room for ever
• Copies can be printed off for offline reading
• Packed with charts, analysis, figures, graphs and tables

Contents

• 1. Executive Summary: Asian Developing Markets for Pharmaceuticals, 2006-2011
• 2. The Global Pharmaceutical Industry Faces Significant Challenges - Will Expansion into Developing Markets Prove to Be the Answer?
  • 2.1 The World Pharmaceutical Market Continues to Grow at a Moderate Rate
  • 2.2 The Principal Markets Are the US, Japan and Leading EU Economies - But Leading Developing Nations Are Narrowing the Gap in Pharmaceutical Revenues
  • 2.3 China is the Ninth Largest World Pharmaceutical Market
  • 2.4 North America, Europe and Japan Continue to Dominate the World Pharmaceutical Market, But Sales in the Developing Markets Are Increasing More Rapidly
  • 2.5 High Growth in the Developing Markets
  • 2.6 China is a Most Exciting Prospect for the Pharmaceutical Industry
  • 2.7 Latin America Exhibits Great Promise for Growth of Pharmaceutical Revenues
  • 2.8 WTO Agreements Affect Pharmaceutical Developments In Emerging Markets
  • 2.9 The Continuing Success of the Pharmaceutical Industry is Dependent Upon Important Drivers and Restraints
  • 2.10 Pharmaceutical Companies Will Jostle Vigorously for Position in Developing Markets
  • 2.11The Pharmaceutical Sector Is Gradually Changing Its Strategic Focus to Overcome Challenges in the Market
  • 2.12 Sales of Generic Products Continue to Encroach Upon the Market for Branded Drugs
  • 2.13 Patent Protection Strategies Form a Cornerstone of Lifecycle Management
  • 2.14 Is Innovation Declining in the Pharmaceutical Industry?
  • 2.15 There Are Strong Forces Acting on Pharmaceutical Pricing In Leading Markets - The Industry Is Under Pressure
  • 2.15.1 The US Branded Market Faces Significant Challenges From Generics and Parallel Trade
  • 2.15.2 Mandatory Price Reductions in Europe Continue to Harass the Pharmaceutical Industry
  • 2.15.3 Governmental Price Controls Are an Established Part of the Japanese Pharmaceutical Market
  • 2.15.4 It Is Possible That Mandatory Cost-Controls in Germany Will Serve As A Precedent For Wider Governmental Controlling of Prices
  • 2.15.5 Reducing Efficiencies in R&D Result in Concerns Over Thinning Pipelines
  • 2.16 Maximising the Impact of Product Launches Yields Commercial Advantages
  • 2.17 Strong Branding is Vital - Both in Established and Emerging Markets
  • 2.18 Expansion Into Developing Countries Will Help to Reinvigorate The Pharmaceutical Industry from 2006-2011
• 3. The Chinese Pharmaceutical Market
  • 3.1 The Chinese Market for Pharmaceuticals Will Expand to $25bn in 2011
  • 3.2 Growth in National and Personal Prosperity Will Raise Demand for Pharmaceutical Products in China
  • 3.3 Remaining Concerns About the Commercial Environment in China Will Act As a Restraint to Market Growth
  • 3.4 The Pharmaceutical Market in China Will be Driven by the Especially Strong Performance of the Chinese Economy from 2005 to 2011
    • 3.4.1 Political and Economic Reform Has Led to a Burgeoning Private Sector - International Pharmaceutical Companies Have Already Established Themselves in China
    • 3.4.2 China's Economic Output May Rise to $4 Billion by 2020
    • 3.4.3 Greater Expectations for Healthcare and Increasing Resources to Pay for Treatments Will Further Drive the Chinese Pharmaceutical Market
    • 3.4.4 Marked Disparities Exist Between the Cities and the Rural Areas - Relative Poverty Is a Continuing Problem for China, With Implications for the Pharmaceutical Market
    • 3.4.5 Both The Chinese Economy and Its Pharmaceutical Market Benefit from Having the World's Largest Population and Labour Force
    • 3.4.6 Expansion of Education and Training in China Will Increasingly Benefit the Pharmaceutical Sector
  • 3.5 The State Food and Drug Administration is The Main Pharmaceutical Regulator in China
  • 3.6 Western Medicine is Gradually Superseding Traditional Medications in China
  • 3.7 Yangzijiang Pharmaceutical Was the Market Leader in 2005 With International Pharmaceutical Leaders Also Performing Well
    • 3.7.1 Novartis Is a Leading Pharmaceutical Investor in China
    • 3.7.2 Pfizer Reported Initiatives to Expand its Presence In China and To Align Itself More Closely With Healthcare Authorities
    • 3.7.3 Novo Nordisk Recently Announced Expansion of Production in China
  • 3.8 Mandatory Pricing Reductions Cause Some Concerns to the Industry
  • 3.9 The Centralised Tendering System Has an Effect on Pharmaceutical Revenues
  • 3.10 Counterfeiting and the Violation of Patents Are Still Problematical In China
  • 3.10.1 Protection of Intellectual Property is Gradually Improving In China But Serious Concerns Remain
  • 3.10.2 Many Sales of Counterfeits and Illegal Generics Occur via the Internet
  • 3.10.3 Pfizer Recently Initiated an Anti-Counterfeiting Programme in Shanghai
  • 3.10.4 The Chinese Authorities Are Tightening Regulations and Enforcement
  • 3.11 That China is The Largest and Most Attractive Developing Market
• 4. The Indian Pharmaceutical Market
  • 4.1 The Indian Pharmaceutical Market Will Expand Rapidly from 2005-2011
  • 4.2 The Indian Pharmaceutical Market Will Benefit from Many Important Drivers
  • 4.3 Potential for Growth In the Indian Market Is Exciting, But Poverty and Lack of Developments Remain Serious Hurdles
  • 4.4 India Is the Second Fastest Growing Major Economy After China
  • 4.5 Political And Economic Reforms Have Eased India's Transition into the Modern, Globalised Economy
  • 4.6 Widespread Poverty Remains a Major Problem in India - There is a Vast Potential Market for Pharmaceuticals But Usually Only Limited Resources for Purchasing Branded Drugs
  • 4.7 India Has an Expanding Professional Class Which Serves As a Strong Driver of Growth in The Pharmaceutical Market
  • 4.8 Domestic Companies Generated 75% of Sales in the Indian Pharmaceutical Market in 2005
    • 4.8.1 Leading International Brands are Aimed at More Exclusive Market Niches Than Cheaper Domestic Products
    • 4.8.2 India Has a Particularly Strong Generics Industry - With the Profile of That Sector Growing Internationally Despite Reduced Domestic Opportunities
    • 4.8.3 The Re-Introduction of Patent Protection Will Increasingly Drive the Market for Branded Products, Especially Those From International Companies
    • 4.8.4 Indian Companies Are Engaging in Joint Ventures and Spin-Off Ventures to Perform Original R&D
    • 4.8.5 The Indian Pharmaceutical Sector is Attractive to Foreign Investors
  • 4.9 State Governments Are Responsible for Providing Healthcare - However Patients Are Very Reliant on The Private Sector
    • 4.9.1 The National Rural Health Mission (NRHM) Should Provide a Significant Boost to Public Healthcare
    • 4.9.2 Physicians Often Make Prescribing Decisions Based Upon the Resources of the Patient
    • 4.9.3 Changes to the Indian Pricing System are Imminent
    • 4.9.4 The Government in Combination With the Gates Foundation Has Announced the Establishment of Public Health Institutes in India
  • 4.10 India Currently Has A Fragmented Procedure for Drug Approval - The Establishment of a National Drugs Agency Should Rationalise the Process
  • 4.11 India Is a Highly Attractive Location for R&D Activities
  • 4.12 The Indian Pharmaceutical Market: Conclusions
• 5. Other Developing Pharmaceutical Markets in Asia
  • 5.1 Asia Constitutes the World's Largest Developing Market for Pharmaceuticals, With Immense Potential for Growth from 2005 to 2011
  • 5.2 Developing Asian Pharmaceutical Markets Have Important Advantages for Companies
  • 5.3 Low Per Capita Healthcare Spending Constitutes the Most Significant Restraint to the Asian Pharmaceutical Market
  • 5.4 It is Not Yet Clear How Well Public and Private Initiatives Will Raise Standards of Healthcare Consistently in Asia
  • 5.5 Prices in Asia Face Increasing Pressure from Governmental Controls and Market Forces
  • 5.6 Protection of IP is a Key Concern in Asia
  • 5.7 Markets for Generics Will Show Continuing Growth as Asian Markets Depend Heavily on Basic Drugs
  • 5.8 The Asian Market Will Be Strongly Driven by Growth in Key Therapeutic Categories
  • 5.9 The Pharmaceutical Market in South Korea
    • 5.9.1 The US Welcomes South Korea's New Policy on Pharmaceuticals
  • 5.10 The Pharmaceutical Market in Turkey
  • 5.11 The Pharmaceutical Market in Taiwan
  • 5.12 The Pharmaceutical Market in Indonesia
  • 5.13 The Pharmaceutical Market in the Philippines
  • 5.14 The Pharmaceutical Market in Thailand
  • 5.15 Overview of Developing Pharmaceutical Markets in Asia
• 6. Conclusions
  • 6.1 China Will Produce the Largest Revenues of All the Developing Pharmaceutical Markets As Well As the Highest Growth Rate
  • 6.2 Overall Growth of the Leading Developing Markets from 2005-2011 Will Be More than Twice that of the Global Pharmaceutical Market
  • 6.3 The Leading Developing Markets Combined Will Generate More Than a Sixth of Global Pharmaceutical Revenues in 2011
  • 6.4 The Main Drivers of Developing Markets Will Be Increasing Prosperity and High Un-met Needs for Modern Treatments
  • 6.5 The Main Restraint to Growth Will Be Continuing Poverty in the Developing World
• List of Tables
  • Table 2.1 Revenue Generation ($bn) by the World Pharmaceutical Industry, 1999-2005
  • Table 2.2 Forecast Revenue Generation ($bn) by the World Pharmaceutical Market, 2005-2011
  • Table 2.3 Top 20 Ranking Nations in the Global Pharmaceutical Market, 2005
  • Table 2.4 How the Top 10 Markets Compared With The Rest of the World, 2005
  • Table 2.5 World Pharmaceutical Revenues ($bn) by Region, 2005
  • Table 2.6 Revenues ($bn), Growth (%) and Market Share (%) for Leading Developing Markets, 2005
  • Table 2.7 Combined Revenues ($bn), Growth (%) and Market Share (%) for Leading Developing Markets by Region, 2005
  • Table 2.8 A SWOT Analysis for Developing Pharmaceutical Markets, 2006-2011
  • Table 2.9 The 10 Most Populous Countries - 2005 and 2030 Compared
  • Table 3.1 Pharmaceutical Revenues ($bn) for China, 2005-2011
  • Table 3.2 China: Fundamental Demographics and Healthcare Economics
  • Table 4.1 Pharmaceutical Revenues ($bn) for India, 2005-2011
  • Table 4.2 India: Fundamental Demographics and Healthcare Economics
  • Table 5.1 Revenues ($bn) for Leading Markets in Asia, 2005-2011
  • Table 5.2 Pharmaceutical Revenues ($bn) for South Korea, 2005-2011
  • Table 5.3 South Korea: Fundamental Demographics and Healthcare Economics
  • Table 5.4 Pharmaceutical Revenues ($bn) for Turkey, 2005-2011
  • Table 5.5 Turkey: Fundamental Demographics and Healthcare Economics
  • Table 5.6 Pharmaceutical Revenues ($bn) for Taiwan, 2005-2011
  • Table 5.7 Taiwan: Fundamental Demographics and Healthcare Economics
  • Table 5.8 Pharmaceutical Revenues ($bn) for Indonesia, 2005-2011
  • Table 5.9 Indonesia: Fundamental Demographics and Healthcare Economics
  • Table 5.10 Pharmaceutical Revenues ($bn) for the Philippines, 2005-2011
  • Table 5.11 Philippines: Fundamental Demographics and Healthcare Economics
  • Table 5.12 Pharmaceutical Revenues ($bn) for Thailand, 2005-2011
  • Table 5.13 Thailand: Fundamental Demographics and Healthcare Economics
  • Table 6.1 The Leading Developing Markets Ranked in Order of Potential Revenue Generation ($bn), 2011
  • Table 6.2 Developing Markets Ranked by Growth Rate (CAGR %), 2005-2011
  • Table 6.3 Revenues ($bn) for Leading Developing Markets by Region, 2005-2011
  • Table 6.4 Share (%) of the World Market by Developing Region, 2005-2011
• List of Figures
  • Figure 2.1 Revenue Generation ($bn) by the World Pharmaceutical Industry, 1999-2005
  • Figure 2.2 Forecast Revenue Generation ($bn) by the World Pharmaceutical Market, 2005-2011
  • Figure 2.3 World Pharmaceutical Revenues ($bn) by Region, 2005
  • Figure 2.4 World Market Share (%) by Region, 2005
  • Figure 2.5 Growth Rates (%) from Previous Year by Region, 2005
  • Figure 2.6 The Increasing Average Cost ($m) of NME Development, 1976-2005
  • Figure 3.1 Pharmaceutical Revenues ($bn) for China, 2005-2011
  • Figure 3.2 World Market Share (%) for China - 2005 and 2011 Compared
  • Figure 3.3 Breakdown (%) of the Chinese Market ($bn) by Conventional Prescription Drugs, OTC Products and Traditional Chinese Medicines, 2005
  • Figure 3.4 Estimated Revenues of Leading Companies in the Chinese Pharmaceutical Market, 2005
  • Figure 3.5 Leading Therapeutic Areas ($m) In the Chinese Pharmaceutical Market, 2005
  • Figure 4.1 Pharmaceutical Revenues ($bn) for India, 2005-2011
  • Figure 4.2 World Market Share (%) for India - 2005 and 2011 Compared
  • Figure 4.3 Breakdown (%) of India's GDP by Sector, 2005
  • Figure 4.4 Sales of Leading Companies in the Indian Market, 2004
  • Figure 4.5 Leading Therapeutic Areas ($m) In the Indian Pharmaceutical Market, 2005
  • Figure 4.6 A Breakdown (%) of the Indian Government's Budget for Healthcare, 2006-2007
  • Figure 5.1a Revenues ($bn) for Leading Markets in Asia, 2005-2011
  • Figure 5.1b Revenues ($bn) for Leading Markets in Asia, 2005-2011
  • Figure 5.2 Combined Revenues ($bn) for Leading Markets in Asia, 2005-2011
  • Figure 5.3 Growth Rates (% CAGR) for the Asian Developing Markets, 2005-2011
  • Figure 5.4 Pharmaceutical Revenues ($bn) for South Korea, 2005-2011
  • Figure 5.5 World Market Share (%) for South Korea - 2005 and 2011 Compared
  • Figure 5.6 Pharmaceutical Revenues ($bn) for Turkey, 2005-2011
  • Figure 5.7 World Market Share (%) for Turkey - 2005 and 2011 Compared
  • Figure 5.8 Pharmaceutical Revenues ($bn) for Taiwan, 2005-2011
  • Figure 5.9 World Market Share (%) for Taiwan - 2005 and 2011 Compared
  • Figure 5.10 Pharmaceutical Revenues ($bn) for Indonesia, 2005-2011
  • Figure 5.11 World Market Share (%) for Indonesia - 2005 and 2011 Compared
  • Figure 5.12 Pharmaceutical Revenues ($bn) for the Philippines, 2005-2011
  • Figure 5.13 World Market Share (%) for the Philippines - 2005 and 2011 Compared
  • Figure 5.14 Pharmaceutical Revenues ($bn) for Thailand, 2005-2011
  • Figure 5.15 World Market Share (%) for Thailand - 2005 and 2011 Compared
  • Figure 6.1 Revenues ($bn) for Leading Developing Markets by Region, 2005-2011
  • Figure 6.2 Revenues ($bn) for Leading Markets of Developing Regions Combined, 2005-2011
  • Figure 6.3 Share (%) of the World Market by Developing Region, 2005-2011
  • Figure 6.4 Share (%) of the World Market by Developing Regions Combined, 2005-2011